Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PFE crawled time : 05:00 save search
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Published: 2023-09-07 (Crawled : 05:00) - globenewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: -0.55%
candidate disease report vaccine positive valneva results phase 2
Pfizer, Teva Pharmaceuticals, Silverstein Properties and Azrieli Group Honored by the America-Israel Friendship League at its Annual Gala
Published: 2022-11-02 (Crawled : 05:00) - prnewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.5%
H: 0.84%
C: -1.47%
teva group
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
Published: 2022-06-06 (Crawled : 05:00) - prnewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 1.12%
H: 0.99%
C: 0.13%
approval cancer
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
Published: 2022-04-12 (Crawled : 05:00) - globenewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -1.17%
H: 1.18%
C: -0.36%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -22.06%
H: 9.34%
C: -3.89%
myfembree management drug application
Arena Pharmaceuticals INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arena Pharmaceuticals, Inc. - ARNA
Published: 2022-01-05 (Crawled : 05:00) - prnewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.73%
H: 0.0%
C: 0.0%
als
Arena Pharmaceuticals INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arena Pharmaceuticals, Inc. - ARNA
Published: 2021-12-15 (Crawled : 05:00) - prnewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 2.56%
H: 5.0%
C: 4.79%
als
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
Published: 2021-07-19 (Crawled : 05:00) - globenewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.17%
H: 0.7%
C: 0.2%
disease phase 2 vaccine trial
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
Published: 2021-06-09 (Crawled : 05:00) - biospace.com/
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.39%
H: 2.15%
C: 2.08%
fda vaccine fda approval order pneumococcal
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
Published: 2020-12-12 (Crawled : 05:00) - globenewswire.com
BNTX | $86.17 -0.27% -0.24% 520K
|
Health Technology
| Email alert
Add to watchlist
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
| Email alert
Add to watchlist
covid vaccine authorized covid-19
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
AULT | $0.2421 -7.7% 45.23% 16M
|
Manufacturing
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
TIRX | $0.8 65.02% 25.95% 410K
|
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
UMAC | $1.55 0.65% 12.9% 0
|
TAOP | $1.08 13.01% 11.51% 19K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.